Intraoperative Floppy Iris Syndrome: Updated Perspectives
Received 3 January 2020
Accepted for publication 11 February 2020
Published 20 February 2020 Volume 2020:14 Pages 463—471
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Chrysanthos D Christou,* Ioannis Tsinopoulos, Nikolaos Ziakas, Argyrios Tzamalis*
2nd Department of Ophthalmology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
*These authors contributed equally to this work
Correspondence: Argyrios Tzamalis
2nd Department of Ophthalmology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
Tel +30 69 4206 0467
Fax +30 23 1332 3974
Email [email protected]
Abstract: Almost fifteen years since its initial description, intraoperative floppy iris syndrome (IFIS) during phacoemulsification surgery remains a challenge for cataract surgeons in all its key aspects that include the stratification of the preoperative risk, preoperative prophylaxis treatment, surgery design and intraoperative management. Since its original association with tamsulosin intake, IFIS has been positively correlated with a plethora of risk factors which include: gender, age, hypertension, other a1-adrenergic receptor antagonists, finasteride, angiotensin II receptor inhibitors, benzodiazepines, antipsychotics, hypertension drugs and decreased dilated pupil diameter. The assessment and stratification of the preoperative risk is pivotal in screening patients prone to develop IFIS. For these patients, it is essential that preoperative prophylaxis, employment of necessary measures and surgical technique modifications are considered. A multidisciplinary approach of IFIS is a mandate, thus ophthalmologists, urologists and sometimes other specialties should cooperate to “educate” each other about the risks of their respective fields. They both must be aware of the joint statement on IFIS by the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery which suggests either the initiation of tamsulosin after phacoemulsification or the use of a non-selective a1-ARA for benign prostatic hyperplasia treatment. In conclusion, awareness of the risk factors associated with IFIS and their detailed preoperative documentation is crucial in addressing IFIS. The lack of such an awareness can turn a routine, uneventful surgery into one with significant visual morbidity.
Keywords: intraoperative floppy iris syndrome, IFIS, risk factors, preoperative prophylaxis, intraoperative management
Intraoperative floppy iris syndrome (IFIS) was primarily reported in 2005.1 In their original article, Chang and Campbell defined IFIS as the presence of the following triad during phacoemulsification surgery: i. tendency of the iris to prolapse through corneal/limbal incisions; ii. a flaccid iris stroma that undulates and billows during surgery; and iii. a progressive intraoperative miosis. IFIS is classified based on the presence of the above signs as grade 0, 1 (mild), 2 (moderate) and 3 (severe).2
The overall reported prevalence of IFIS is 1.1–12.6%1,3,4, yet several risk factors are positively corelated with IFIS, thus significantly increasing the risk of its appearance. Beyond the original correlation with tamsulosin intake,1 IFIS has been correlated with several risk factors which include: gender, age, hypertension, other a1- adrenergic receptor antagonists (a1-ARAs), finasteride, angiotensin II receptor inhibitors, benzodiazepines, antipsychotics, hypertension drugs and decreased dilated pupil diameter.5–10 The careful preoperative assessment of these predisposing factors is essential in the stratification of the preoperative risk. As a matter of fact, IFIS is associated with higher rate of complications, that include increased ocular inflammation, posterior capsule rupture, anterior capsule tears, vitreous loss, iris trauma, cystoid macular edema and hyphema.1,11,12 High-risk patients may be candidates for prophylaxis treatment and the employment of necessary measures and surgical technique modifications that will address the needs of IFIS management and minimize complications.
Almost fifteen years since its initial description, IFIS still remains a challenge for cataract surgeons in all its aspects. Our study aims to review the existing literature, address all these challenges and provide an updated perspective in the prophylaxis and management of IFIS. We, hereby, provide a comprehensive up-to-date review of the literature associated with intraoperative floppy iris syndrome. Eligible articles were identified by a search of the bibliographic database in PubMed using the following combination of search terms: (intraoperative floppy iris syndrome) OR (IFIS) OR (floppy iris AND cataract surgery) OR (floppy iris AND phacoemulsification). The end of the search date was December 18, 2019. We also checked all the references of relevant reviews and eligible articles that our search retrieved. Language restrictions were not used, and data were extracted from each eligible study by 2 investigators working independently (AT, CC). No restrictions were placed upon our search in terms of year of publication.
The appearance of intraoperative floppy iris syndrome has been shown to be affected by many reasons and various systemic medications.5–10 However, IFIS came in the spotlight when the therapeutic algorithm for the treatment of benign prostatic hyperplasia (BPH) suggested the intake of a1-ARA as the first line treatment, substituting surgical intervention.13 Three subtypes of a1- adrenergic receptors (a1- AR) have been identified so far: a1A, a1B and a1D. a1A AR is the main regulator of smooth muscle tone in the human urinary system and dominates also the musculus dilatator pupillae.14 a1B subtype regulates blood pressure through arterial muscle relaxation.14 The choroid as a highly vascularized layer is rich in a1B ARs, thus all a1B-ARAs have potential effects on the choroidal blood flow. a1D is associated with contraction of the bladder muscle and sacral spinal cord innervation.14 In the early stages of a1-ARAs intake, they antagonize the a1-receptors within the dilator muscle of the iris, thus preventing the iris from fully dilating during cataract phacoemulsification.1
The discontinuation of a1-ARAs and/or the use of epinephrine which displaces a1-ARAs may theoretically lead to an increase of the iris tone and a decrease of IFIS incidence. However, cases of severe IFIS do not benefit significantly from either measure which implies a different mechanism through which a1-ARAs act upon the iris.15,16 It is proposed that the long-term intake of a1-ARAs leads to permanent anatomical variations, which are incompletely resolved after treatment interruptions and are not affected by the use of mydriatic agents.17 In addition, the drug-melanin interaction causes further dilator muscle atrophy that contributes to the development of IFIS.16
Other systemic medication such as benzodiazepines, antipsychotics and hypertension drugs may have a similar effect on the iris, although the exact pathophysiological mechanism has not been fully understood and the correlation with IFIS incidence does not seem to be as strong as with tamsulosin.4,5,7 Cataract surgery is one of the most frequently performed surgeries worldwide.18 Similarly, BHP is present in almost 50% of men by the age of 50 years and 75% of men by the age of 80 years.19 Therefore, it is only natural, that with the life expectancy elongation, men with BHP on a1-ARAs treatment requiring cataract phacoemulsification surgery or vice versa, would be the norm.
The positive correlation of tamsulosin and IFIS is well established since the initial description of this phenomenon.1 Along with alfuzosin, they are the most commonly prescribed ARAs.20 Tamsulosin blocks equally a1A and a1D ARs with an affinity ten times greater than other a1-ARAs,21 thus tamsulosin has the higher odds ratio (OR=206.5) and relative risk ratio (RR=99.3) for IFIS development among a1-ARAs.22 The recommended daily dosage in Japan is 0.2mg while in Europe and the US is 0.4mg.23 It is of note, that studies originating from Japan report lower IFIS incidence among men on tamsulosin than the incidence reported in Europe and the U.S.23 Therefore, IFIS development for patients on tamsulosin is probably positively corelated with its cumulative dosage. However, development of IFIS has been reported even after 48 hrs of tamsulosin intake.24
The discontinuation of tamsulosin 4–7 days prior to surgery might be beneficial, although it does not prevent IFIS completely.1,13 Due to its high OR and RR for IFIS, it is recommended that urologists inform their patients for the risk of IFIS before prescribing tamsulosin. Ideally, the ophthalmologist of the patient should be notified.25 Patients requiring cataract surgery, could be scheduled for surgery before the initiation of tamsulosin. Alternatively, a non-selective a1-ARA can be considered.
Alfuzosin, doxazosin and terazosin block equally all three a1-AR subtypes.21 Due to their decreased affinity for the a1A-AR, they have lower ORs and RRs for the development of IFIS compared to tamsulosin.2 Their increased affinity for the a1B-ARs (located in the blood vessels) causes hypotension.26–28 Therefore, these non-selective a1-ARAs could be used when BPH and hypertension coexist. In men with symptomatic BPH and cataract, the initiation of alfuzosin is considered by many physicians as the first-line treatment as its risk of causing IFIS is up to 30 times smaller than with tamsulosin.2 In a study which compared the effect that systemic alfuzosin or tamsulosin intake has on choroidal thicknesses (CT) and pupil diameter size (PD), alfuzosin was found to significantly decrease both CT and PD.29 Tamsulosin on the other hand, did not affect CT, which makes sense since it does not antagonize the a1B AR. Considering PD, the alfuzosin group showed significantly smaller pupils than the tamsulosin group. The authors proposed that alfuzosin leads to IFIS due to its a1-AR blockage while tamsulosin causes additional atrophy of the iris dilator muscle.29
Two additional new a1-ARAs have been recently released, silodosin and naftopidil. Similarly to tamsulosin, they are not supposed to cause hypotension. Silodosin has the following affinity for a1-ARs: a1A>a1D>a1B and a high affinity for melanin,16,21 while naftopidil has the following affinity: a1D=a1A>a1B.21 Silodosin has already been characterized as the causative agent in some cases with IFIS.16,30,31 Further prospective randomized studies are expected to quantify the exact risk of developing IFIS with these newer medications.
Except from a1-ARAs, several other drugs have been corelated with IFIS. Finasteride inhibits the type II and III isoenzyme of 5a-reductase enzyme, thus decreasing the levels of the serum dihydrotestosterone.32 It is commonly used in BHP treatment and it has been linked with cases of anterior subcapsular cataracts and IFIS.6,32 Therefore, some authors propose its discontinuation prior to cataract surgery.6,32 Angiotensin II receptor inhibitors have also been implicated as a main predisposing factor for IFIS, particularly in women, although it has not been established yet whether particular medication or arterial hypertension itself could be the main contributing factor to the development of floppy iris.8
In addition, several neuromodulators including benzodiazepines, donepezil and duloxetine have been associated with IFIS by several studies.5,7,33,34 In a large retrospective study, Chatziralli et al reported an increased incidence of IFIS in patients receiving benzodiazepines, an association that was confirmed in a univariate analysis by Kaczmarek et al.5,7 In 2007 Papadopoulos et al reported IFIS in a patient with long history (8 years) of donepezil intake for Alzheimer’s disease, while recently González-Martín-Moro et al published a case of IFIS in a patient receiving duloxetine as antidepressant for 3 years.33,34 The increased incidence of IFIS in patients treated with the above-mentioned medications might be either causative or coincidental. Although cholinergic medications are known to oppose mydriasis, the exact pathogenetic mechanism through which these drugs contribute to IFIS development is less clear and remains subject for future studies. Nonetheless, it is advisable that patients are always preoperatively asked regarding intake of these medications and surgeons should be aware of the possibility of IFIS.
Regarding antipsychotics, typical and atypical antipsychotics, including quetiapine, chlorpromazine, zuclopenthixol, aripiprazole and risperidone have been associated with IFIS.5,35–39 These reported cases responded well to the use of intracameral epinephrine, this suggesting that the a1-antagonism was probably the causative mechanism.36–39
Gender and Age
Regarding gender, a strong positive correlation has been found between IFIS and male sex.5,7,9,40 The significantly higher prevalence of IFIS among men, can obviously be attributed to the intake of a1- ARAs for BHP treatment. IFIS however, occurs in females too, although less commonly than in males, thus women are unfortunately often overlooked as high-risk candidates for IFIS development.9 Notably, IFIS in women has been correlated with a higher incidence of intraoperative complications than in men, including posterior capsule rupture, vitreous loss, nucleus drop and endothelial cell loss, leading in a significantly worse final visual outcome.9 Clinicians should not forget that females, although less frequently than men, are also prescribed a1- ARAs for outlet obstruction and detrusor underactivity, as well as other drugs that are related to IFIS such as benzodiazepines, angiotensin receptor inhibitors and antipsychotics. All these predisposing factors should be clearly documented during preoperative visits in order to avoid unanticipated IFIS that could have a detrimental effect to the surgical outcome.
As far as patient age is concerned, IFIS has been positively correlated in a recent prospective study with advanced age, yielding a proposed adjusted OR for each 1-year increase in age, 1.09 (95% CI 1.03–1.16, P=0.006).7 Pathogenetically, the potency of norepinephrine is proportional to the receptor reserve in the iris dilator muscle which is altered with aging.41 In addition, a study which used the incidence of fluorescein leakage as an iris vasculature dysfunction indicator, suggested a positive correlation between aging and vasculature dysfunction.42
The impact of hypertension in the development of IFIS remains controversial. The proposed pathogenetic mechanism suggests that systemic diseases cause endothelial dysregulation that lead to increased resistance of the iris dilator muscle to adrenergic agonists.43 Using immunochemistry, it has been confirmed that a1A-ARs are located in the human iris arteriolar muscularis in addition to the iris dilator muscle.44 However, the existing literature is unclear with several studies reporting no correlation between hypertension and IFIS development7,45 and other studies reporting statistical significance.5,45 Therefore, it is unclear whether the increased risk in the development of IFIS should be attributed to hypertension as an independent risk factor or whether it is associated with specific antihypertensive drugs.
Dilated Pupil Diameter
Decreased preoperative dilated pupil diameter has been proposed as an independent risk for the development of IFIS regardless of a1-ARAs intake.10,46 Several cut-off values have been proposed ranging from 6.5–8mm.2,10,46,47 It has been reported that a dilated pupil of 7.0mm or smaller had 73% sensitivity and 95% specificity for predicting IFIS in patients being treated with a1- ARAs.46 Since pupil and cornea sizes are different among races and individuals,48 the dilated pupil to limbal diameter ratio was proposed as a more objective measurement for IFIS development prediction.47 A ratio less than 0.6 was found positively corelated with the development of IFIS.47
Preoperative Assessment and Prophylaxis
Even though numerous studies have investigated several risk factors, a unified risk stratification system that evaluates all risk factors and predicts with high sensitivity and specificity the chance of IFIS development, is absent. Until such a clinical tool is available, it is strongly recommended that a detailed medical history is taken that thoroughly evaluated all risk factors which have been associated with IFIS. As mentioned above, specific medication intake (tamsulosin, other a1- ARAs, antipsychotics, benzodiazepines, anti-hypertensive drugs) should always be documented in the preoperative control and further clinical data including arterial hypertension, advanced patient age and small dilated pupil size should also be recorded.
The discontinuation of drugs with a causative relationship to IFIS such as tamsulosin does not seem to fully eliminate the risk of developing IFIS although it might be helpful sometimes.1,13 In their initial description, Chang et al concluded that withdrawal of tamsulosin 4–7 days prior cataract surgery might prevent IFIS in some cases but not completely.1 Tamsulosin has a relatively long half-life and can irreversibly block a1 adrenoceptors or induce permanent iris atrophy. Therefore, a discontinuation period of several days might be insufficient. Although many surgeons anecdotally tend to withdraw, when possible, tamsulosin and alfuzosin prior to cataract surgery, there is no strong evidence in the literature that such a withdrawal can be of help.40
In addition, to date, there is no consensus on a definitive preventive strategy for the development of IFIS in high-risk patients. It is therefore up to the ophthalmologist to stratify the risk for each patient and decide the patients for whom a preoperative prophylaxis and surgical technique modifications are needed. Preoperative use of topical atropine as a parasympatholytic agent with or without the use of intracameral epinephrine reduces the incidence of IFIS in high-risk patients.17,49,50 A recent study proposed that atropine sulfate 1% instillation at 40 and 20 mins prior to surgery significantly reduces IFIS incidence and especially its mild forms.17 It is of note that many surgeons favour the use of pre-operative topical non-steroidal anti–inflammatory drugs (NSAIDs) such as ketorolac to facilitate pupillary mydriasis during cataract surgery, as these drugs block cyclo-oxygenase and inhibit prostaglandins from causing pupillary miosis intraoperatively. A relevant study which investigated the use of topical NSAIDs in high risk patients (dilated pupil<5mm), found that the need for iris fixation ring insertion to maintain pupil dilation or to control IFIS was reduced from 50% in the control group (epinephrine) to 0% in the study group (epinephrine/ketorolac, p=0.0034).51 Mean surgical time was also significantly shorter in the study group (p=0.0068).
Surgical Management of IFIS
Beyond preoperative prophylaxis, for patients associated with a high risk to develop IFIS, protocols should ensure that the hazard is highlighted before surgery and necessary measures and surgical technique modifications are employed. Primarily, these patients should be assigned to the most senior members of the surgical team.9,10 Then, careful incision location and construction along with the use of less aggressive, low-flow phacoemulsification fluidic parameters are effective in controlling iris behavior and lead to milder cases of IFIS.9,13 Further slight modifications such as gentle hydrodissection, minimization of in-and-out movements and keeping the irrigation flow above the iris plane could be helpful.22 In addition, the use of anterior elongated corneal incisions has been reported to reduce the incidence and severity of IFIS for dilated pupils no less than 4.5mm.52
Maintenance of an adequately dilated pupil is crucial for optimal and accurate visualization,53 thus during a surgery that is complicated with an unanticipated IFIS, the enlargement of the pupil using pupil expansion rings or iris hooks can be considered.54 Mechanical pupil stretching or partial sphincterotomy are generally not advisable in cases of anticipated IFIS as they may induce further miosis due to irritation of a partially atrophic iris and its abnormal elasticity.1 Furthermore, controlling the iris mechanically, although sometimes effective, requires additional surgical time and increases the postoperative billowing.53,55 Consequently, in cases at high-risk for IFIS, such as male population on tamsulosin with a poor mydriasis, pupil expansion devices are preferably used as a preventive measure from the beginning of surgery rather than after IFIS develops to avoid jeopardizing the integrity of the capsulorrhexis.
Iris retractors, although time consuming, are sometimes preferred by cataract surgeons over pupil expanders due their significantly lower cost and better safety profile in cases with a shallow anterior chamber. When applied, one of the retractors should be located directly beneath the main incision forming a diamond-shape pupil, thus pulling the iris away from the phaco tip and decreasing the risk of iatrogenic iris trauma. In this case, a clear cornea incision is preferred in order to provide adequate space for the sub-incisional retractor tunnel.55 On the other hand, pupil expansion devices are in most cases much easier to use, require less operating time, do not require extra incisions and provide a stable pupil during surgery minimizing postoperative pupil deformity and anterior chamber inflammation.53–55
Healon5® OVD (Johnson & Johnson Vision, Santa Ana, CA) and other viscoadaptive/dispersive ophthalmic viscosurgical devices (OVDs) have been used as a mean for maintaining the pupil dilated intraoperatively.47 Healon5 is generally preferred in cases where low fluidics are used as it can be aspirated easily. Alternatively, in cases where high flow parameters are needed, a dispersive OVD can be used on top of Healon5 in a modified soft-shell technique to ensure better stability of viscomydriasis.56 A sub-tenon injection of 2.5mL of lidocaine 2.5% has also been reported to reduce all features of IFIS in mild-to-moderate cases.57
Intracameral epinephrine and phenylephrine promote pupillary dilation and reduce iris floppiness.58,59 They can be used either at the beginning of surgery for poorly dilated pupils (<4,5mm) or intraoperatively during progressive miosis where they can yield an additional 1mm of dilation.60 The use of intracameral epinephrine has been reported to decrease IFIS incidence in patients receiving a1- ARAs.17 A poorly dilated pupil at the beginning of the surgery after an intracameral epinephrine injection is an early sign of potential IFIS.49 Epinephrine (1:1000) should be adequately diluted before intracameral use in order to avoid corneal endothelial damage. The most common dilution used is 1:3 with Balanced Salt Solution (BSS), resulting in a 1:4000 epinephrine solution.55
It is preferable to use preservative- and bisulfite-free epinephrine and phenylephrine intracamerally. However, these solutions are not always available in the surgical setting and a recent study that was designed to evaluate the intracameral phenylephrine preparations protocols for dosage accuracy, concluded that current protocols are inaccurate and inconsistent, thus the concentration of phenylephrine delivered intracamerally is low and highly variable.61 The use of commercial intracameral phenylephrine products would address this problem.61 FDA recently approved a combination of phenylephrine 1% and ketorolac 0.3% for intraocular use during cataract surgery to prevent intraoperative miosis and iris flaccidity and to decrease postoperative pain.52,62,63 Specifically, Donnenfeld et al designed a randomized clinical trial where patients were randomized administrated with either vehicle or phenylephrine or ketorolac or the study drug containing phenylephrine and ketorolac intracamerally during surgery. Regarding the maintenance of mydriasis, the percentages of patients with an intraoperative pupil diameter <6mm were 47.2% for the vehicle, 22.4% for the phenylephrine, 34.6% for the ketorolac and 6.1% for the study drug.63 These results of the fixed combination are promising so far, as it is shown to reduce the incidence of IFIS in patients receiving tamsulosin and maintain intraoperative mydriasis, either injected intracamerally or being added to the irrigation solution during cataract surgery.62,63
Although pupil constriction minimizing surgical visibility is the main concern of cataract surgeons in IFIS patients, iris prolapse can also be a major intraoperative issue leading to complications such as wound dehiscence, iatrogenic iris injury, postoperative endophthalmitis etc.11,12 In order to deal with iris prolapse, several tricks have been described such as lowering intraocular pressure followed by “milking” the iris back into the anterior chamber.64,65 The key in management is to equalize the pressure gradient by releasing fluid from behind the iris. Additional OVD can also be placed in front of the iris to help in this regard.66 Furthermore, when iris prolapse occurs towards the completion of surgery after IOL implantation, the intracameral injection of miotic agents such as acetylcholine (Miochol-E, Bausch+Lomb) or carbachol (Miostat, Alcon Laboratories) can be of benefit.67
Considering complications, their incidence is significantly higher in an unanticipated IFIS.9,55 Complications related to IFIS may vary from mild and transient to detrimental including posterior capsule rupture, vitreous prolapse, retained lens fragments, iris trauma, wound dehiscence, nuclear drop, postoperative inflammation and intraocular hypertension among others. Fortunately, in verified high-risk patients where preventive measures are employed, complication rates return to their baseline values.54 Specifically, posterior capsule rupture rates in unanticipated IFIS range from 7–12%, where adequate awareness and preventive measures could reduce this rate to almost zero.68
Notably complication rates were found significantly higher in females, where IFIS was not expected as opposed to men receiving a1- ARAs highlighting the need for better preoperative documentation and the establishment of a new stratification system.9 In addition, Campbell et al, in a recent study, descripted that the rates of complications associated with IFIS in their centre, steadily decrease year by year due to the increased awareness for IFIS.69 The long-term consequences of a cataract surgery complicated with IFIS include permanent pupil deformity and vision loss secondary to endophthalmitis, macular edema or retinal detachment.55
This review highlights the pivotal role of preoperative assessment as the key in addressing IFIS. Preoperative prophylaxis and the employment of necessary measures turn the risks of complications back to their baseline.54 The need to apply such measures is dictated by increased prevalence of IFIS among high-risk groups. Unanticipated IFIS is still corelated with high rates of complications.9 There are several limitations of this review. The retrospective character of some of the studies included and the small sample size of case series analyzed, especially when it comes to subgroups analysis, raises doubts about the conclusiveness of their findings. Further prospective randomized clinical trials are needed to draw safe conclusions. Such studies could lead to the development of a unified preoperative assessment clinical tool that will stratify the potential risk and predict IFIS with high sensitivity and specificity.
The fact that along with life expectancy elongation more and more patients with BHP on ARAs intake would require cataract surgery, dictates that urologists, ophthalmologists and general practitioners should cooperate to address this tendency. They must all be aware of the joint statement on IFIS by the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery which suggests either the initiation of tamsulosin after phacoemulsification or the use of a non-selective a1-ARA for BPH treatment.70 In conclusion, proper identification of predisposing factors related to the development of IFIS and thorough preoperative documentation is crucial in managing IFIS and avoiding associated complications that could significantly increase visual morbidity.
The authors report no conflicts of interest in this work.
1. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–673. doi:10.1016/j.jcrs.2005.02.027
2. Chang DF, Campbell JR, Colin J, Schweitzer C; Study Surgeon Group. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology. 2014;121:829–834. doi:10.1016/j.ophtha.2013.10.031
3. Cheung CM, Awan MA, Peh KK, Sandramouli S. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist. Am J Ophthalmol. 2007;143(6):1070. doi:10.1016/j.ajo.2007.02.044
4. Wahl M, Tipotsch-Maca SM, Vecsei-Marlovits PV. Intraoperative floppy iris syndrome and its association with various concurrent medications, bulbus length, patient age and gender. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):113–118. doi:10.1007/s00417-016-3515-7
5. Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P. Risk factors for intraoperative floppy iris syndrome: a prospective study. Eye (Lond). 2016;30(8):1039–1044. doi:10.1038/eye.2016.122
6. Issa SA, Dagres E. Intraoperative floppy-iris syndrome and finasteride intake. J Cataract Refract Surg. 2007;33(12):2142–2143. doi:10.1016/j.jcrs.2007.07.025
7. Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019;39(3):541–549. doi:10.1007/s10792-018-0840-3
8. Tzamalis A, Malyugin B, Ziakas N, Tsinopoulos I. Angiotensin receptor inhibitors as main predisposing factor for intraoperative floppy iris syndrome in women. J Cataract Refract Surg. 2019;45(5):696–697. doi:10.1016/j.jcrs.2019.01.034
9. Tzamalis A, Matsou A, Dermenoudi M, Brazitikos P, Tsinopoulos I. The role of sex in intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2019;45(1):41–47. doi:10.1016/j.jcrs.2018.08.029
10. Chen AA, Kelly JP, Bhandari A, Wu MC. Pharmacologic prophylaxis and risk factors for intraoperative floppy-iris syndrome in phacoemulsification performed by resident physicians. J Cataract Refract Surg. 2010;36(6):898–905. doi:10.1016/j.jcrs.2009.12.039
11. Muqit MM, Menage MJ. Intraoperative floppy iris syndrome. Ophthalmology. 2006;113(10):1885–1886.
12. Lim LA, Frost A. Iris tears secondary to intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2006;32(10):1777. doi:10.1016/j.jcrs.2006.05.021
13. Lunacek A, Mohamad Al-Ali B, Radmayr C, et al. Ten years of intraoperative floppy iris syndrome in the era of α-blockers. Cent Eur J Urol. 2018;71(1):98–104. doi:10.5173/ceju.2017.1234
14. Schwinn DA, Michelotti GA. α1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1D-subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85 Suppl 2:6–11. doi:10.1046/j.1464-410X.2000.00061.x
15. Zaman F, Bach C, Junaid I, et al. The floppy iris syndrome - what urologists and ophthalmologists need to know. Curr Urol. 2012;6(1):1–7. doi:10.1159/000338861
16. Goseki T, Ishikawa H, Ogasawara S, et al. Effects of tamsulosin and silodosin on isolated albino and pigmented rabbit iris dilators: possible mechanism of intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2012;38:1643–1649. doi:10.1016/j.jcrs.2012.05.025
17. Nuzzi R, Arnoffi P, Tridico F. Best prophylactic strategy in groups at risk of intraoperative floppy iris syndrome development: comparison between atropine instillation and adrenaline intracameral injection. Open Ophthalmol J. 2018;30(12):34–40. doi:10.2174/1874364101812010034
18. Alio JL. Cataract surgery: from today’s standards to future progress. Asia Pac J Ophthalmol (Phila). 2017;6(4):309.
19. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419–426. doi:10.1016/j.juro.2013.04.119
20. Perumal C, Chowdhury PS, Ananthakrishnan N, Nayak P, Gurumurthy S. A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urol Ann. 2015;7(1):74–78. doi:10.4103/0974-7796.148624
21. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15(3):193–199. doi:10.1111/j.1442-2042.2007.01956.x
22. Keklikci U, Isen K, Unlu K, Celik Y, Karahan M. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. Acta Ophthalmol. 2009;87(3):306–309. doi:10.1111/aos.2009.87.issue-3
23. González Martín-Moro J, Muñoz Negrete F, Lozano Escobar I, Fernández Miguel Y. Intraoperative floppy-iris syndrome. Arch Soc Esp Oftalmol. 2013;88(2):64–76. doi:10.1016/j.oftal.2011.09.023
24. Shah N, Tendulkar M, Brown R. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin? Eye (Lond). 2009;23(3):740. doi:10.1038/eye.2008.95
25. Yaycioglu O, Altan-Yaycioglu R. Intraoperative floppy iris syndrome: facts for the urologist. Urology. 2010;76(2):272–276. doi:10.1016/j.urology.2010.01.025
26. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging. 1993;3(3):258–277. doi:10.2165/00002512-199303030-00007
27. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995;49(2):295–320. doi:10.2165/00003495-199549020-00011
28. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993;45(3):410–429. doi:10.2165/00003495-199345030-00008
29. Dogan M, Kutluksaman B, Keles I, Karalar M, Halat AO. The effects of systemic alfuzosin and tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes in cases with benign prostatic hyperplasia. Curr Eye Res. 2017;42(12):1638–1643. doi:10.1080/02713683.2017.1359306
30. Ipekci T, Akin Y, Hoscan B, Tunckiran A. Intraoperative floppy iris syndrome associated with silodosin. Acta Ophthalmol. 2015;93(4):e306. doi:10.1111/aos.2015.93.issue-4
31. Chatterjee S, Agrawal D. Silodosin-associated intraoperative floppy iris syndrome. Indian J Ophthalmol. 2017;65(6):538–539. doi:10.4103/ijo.IJO_704_16
32. Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011;37(7):1351–1354. doi:10.1016/j.jcrs.2011.04.013
33. González-Martín-Moro J, González-López JJ, Zarallo-Gallardo J, Fernández-Miguel Y. Intraoperative floppy iris syndrome after treatment with duloxetine: coincidence, association, or causality? Arch Soc Esp Oftalmol. 2015;90(2):94–96. doi:10.1016/j.oftal.2014.09.005
34. Papadopoulos R, Bachariou A. Intraoperative floppy-iris syndrome associated with chronic intake of donepezil. J Cataract Refract Surg. 2007;33(11):1997–1998. doi:10.1016/j.jcrs.2007.06.054
35. Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology. 2011;118(4):730–735. doi:10.1016/j.ophtha.2010.08.039
36. Bilgin B, Ilhan D, Cetinkaya A, Unal M. Intraoperative floppy iris syndrome associated with quetiapine. Eye (Lond). 2013;27(5):673. doi:10.1038/eye.2013.40
37. Pringle E, Packard R. Antipsychotic agent as an etiologic agent of IFIS. J Cataract Refract Surg. 2005;31:2240–2241.25. doi:10.1016/j.jcrs.2005.12.066
38. Unal M, Yucel I, Tenlik A. Intraoperative floppy-iris syndrome associated with chronic use of chlorpromazine. Eye (Lond). 2007;21:1241–1242. doi:10.1038/sj.eye.6702914
39. Matsuo M, Sano I, Ikeda Y, Fujihara E, Tanito M. Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs. Can J Ophthalmol. 2016;51(4):294–296. doi:10.1016/j.jcjo.2016.02.008
40. Neff KD, Sandoval HP, Fernández de Castro LE, Nowacki AS, DT V, KD S. Factors associated with intraoperative floppy iris syndrome. Ophthalmology. 2009;116(4):658–663. doi:10.1016/j.ophtha.2008.12.026
41. Takayanagi I. Effects of aging on drug receptor mechanisms in smooth muscles. Nihon Yakurigaku Zasshi. 1994;104(3):163–175. doi:10.1254/fpj.104.163
42. Satoh K, Takaku Y, Ohtsuki K, Mizuno K. Effects of aging on fluorescein leakage in the iris and angle in normal subjects. Jpn J Ophthalmol. 1999;43(3):166–170. doi:10.1016/S0021-5155(99)00012-X
43. Schwinn DA, Afshari NA. alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol. 2006;51(5):501–512. doi:10.1016/j.survophthal.2006.06.011
44. Panagis L, Basile M, Friedman AH, Danias J. Intraoperative floppy iris syndrome: report of a case and histopathologic analysis. Arch Ophthalmol. 2010;128(11):1437–1441. doi:10.1001/archophthalmol.2010.243
45. Altan-Yaycioglu R, Gedik S, Pelit A, Akova YA, Akman A. Clinical factors associated with floppy iris signs: a prospective study from two centers. Ophthalmic Surg Lasers Imaging. 2009;40(3):232–238. doi:10.3928/15428877-20090430-02
46. Casuccio A, Cillino G, Pavone C, Spitale E, Cillino S. Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011;37(8):1447–1454. doi:10.1016/j.jcrs.2011.02.030
47. Terauchi Y, Horiguchi H, Shiba T. The pharmacological mydriatic pupil-to-limbal diameter ratio as an intuitive predictor for the risk of intraoperative floppy iris syndrome. J Ophthalmol. 2018;20(2018):2837934.
48. Blake CR, Lai WW, Edward DP. Racial and ethnic differences in ocular anatomy. Int Ophthalmol Clin. 2003;43(4):9–25. doi:10.1097/00004397-200343040-00004
49. Esen F, Bulut AE, Toker E. Efficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome. Cutan Ocul Toxicol. 2018;37(3):286–290. doi:10.1080/15569527.2018.1456448
50. Bendel RE, Phillips MB. Preoperative use of atropine to prevent intraoperative floppy iris syndrome in patients taking tamsulosin. J Cataract Refract Surg. 2006;32(10):1603–1605. doi:10.1016/j.jcrs.2006.04.039
51. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;5(12):301–305. doi:10.2147/OPTH.S149522
52. Blau-Most M, Mimouni M, Geffen N, Segal O, Segev F. Modified corneal incisions for cataract surgery in patients treated with tamsulosin: a prospective study. Curr Eye Res. 2019;44(4):381–384. doi:10.1080/02713683.2018.1557211
53. Bucci FA
54. Chang DF, Osher RH, Wang L, Koch DD. Prospective muticenter evaluation of cataract surgery in patients taking tamsulosin. Ophthalmology. 2007;114(5):957–964. doi:10.1016/j.ophtha.2007.01.011
55. Enright JM, Karacal H, Tsai LM. Floppy iris syndrome and cataract surgery. Curr Opin Ophthalmol. 2017;28(1):29–34. doi:10.1097/ICU.0000000000000322
56. Arshinoff SA. Modified sst-usst for tamsulosin-associated intraoperative [corrected] floppy-iris syndrome. J Cataract Refract Surg. 2006;32:559–561. doi:10.1016/j.jcrs.2006.01.001
57. Klysik A, Korzycka D. Sub‑Tenon injection of 2% lidocaine prevents intra‑operative floppy iris syndrome (IFIS) in male patients taking oral a‑adrenergic antagonists. Acta Ophthalmol. 2014;92:
58. Gurbaxani A, Packard R. Intracameral phenylephrine to prevent floppy iris syndrome during cataract surgery in patients on tamsulosin. Eye (Lond). 2007;21(3):331–332. doi:10.1038/sj.eye.6702172
59. Shugar JK. Use of epinephrine for ifis prophylaxis. J Cataract Refract Surg. 2006;32(7):1074–1075. doi:10.1016/j.jcrs.2006.01.110
60. Manvikar S, Allen D. Cataract surgery management in patients taking tamsulosin staged approach. J Cataract Refract Surg. 2006;32(10):1611–1614. doi:10.1016/j.jcrs.2006.04.037
61. Guthrie S, Jensen T, Hartley RC, Ramaesh K, Lockington D. Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery. Eye (Lond). 2018;32(10):1615–1620. doi:10.1038/s41433-018-0143-y
62. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%-ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103–1108. doi:10.1016/j.jcrs.2018.05.029
63. Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg. 2017;43(5):597–605. doi:10.1016/j.jcrs.2017.02.030
64. Tint NL, Dhillon AS, Alexander P. Management of intraoperative iris prolapse: stepwise practical approach. J Cataract Refract Surg. 2012;38(10):1845–1852. doi:10.1016/j.jcrs.2012.08.013
65. Christiansen SM, Oetting TA. Ten tips to prevent and treat iris prolapse; 2017. Available from: http://EyeRounds.org/tutorials/ten-tips-iris-prolapse.htm.
66. Devgan U. Cataract coach. Managing Mild Iris Prolapse during Phaco; 2018. Available from: https://cataractcoach.com/2018/10/05/managing-mild-iris-prolapse-during-phaco/.
67. Guruswami G. Medscape. Iris Prolapse Treatment & Management; 2015. Available from: https://emedicine.medscape.com/article/1209310-treatment#d7.
68. Nguyen DQ, Sebastian RT, Kyle G. Surgeon’s experiences of the intraoperative floppy iris syndrome in the United Kingdom. Eye (Lond). 2007;21(3):443–444. doi:10.1038/sj.eye.6702616
69. Campbell RJ, El-Defrawy SR, Gill SS, et al. Evolution in the risk of cataract surgical complications among patients exposed to tamsulosin: a population-based study. Ophthalmology. 2019;126(4):490–496. doi:10.1016/j.ophtha.2018.11.028
70. Intraoperative Floppy Iris Syndrome (IFIS). Associated with systemic Alpha‐1 Antagonists ASCRS and AAO educational update statement. Available from: https://ascrs.org/.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.